(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Byars NE and Allison AC | Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. | 1987 | Vaccine | pmid:3499713 |
Minutello M et al. | Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. | 1999 | Vaccine | pmid:9987141 |
Iorio AM et al. | Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. | 2003 | Vaccine | pmid:12922092 |
Madhun AS et al. | An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. | 2010 | Vaccine | pmid:21034828 |
Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
Pellegrini M et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | 2009 | Vaccine | pmid:19751689 |
Forrest HL et al. | Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. | 2009 | Vaccine | pmid:19406182 |
Ansaldi F et al. | Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. | 2010 | Vaccine | pmid:20433807 |
Camilloni B et al. | An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. | 2010 | Vaccine | pmid:20846530 |
Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
Puig-Barberà J et al. | Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. | 2007 | Vaccine | pmid:17889411 |
Wack A et al. | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | 2008 | Vaccine | pmid:18162266 |
Yu S et al. | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. | 2012 | Vaccine | pmid:22709954 |
Chandramouli S et al. | Generation of a parvovirus B19 vaccine candidate. | 2013 | Vaccine | pmid:23827313 |
Nielsen AB et al. | Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. | 2012 | Vaccine | pmid:23036498 |